Iberdomide

Summary

Iberdomide (CHEMBL3989927) is a phase-3 clinical-stage small molecule targeting CRBN; indicated across 2 conditions including plasma cell myeloma and kidney failure.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (CRBN)
• Indications: 2 conditions
• Clinical trials: 47
• Chemistry: 449.5 Da · C25H27N3O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989927
Name	Iberdomide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	67335295
Molecular formula	C25H27N3O5
Molecular weight	449.5
InChIKey	IXZOHGPZAQLIBH-NRFANRHFSA-N

SMILES: C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5

IUPAC name: (3S)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione

Also known as: CC-220, Iberdomida, Iberdomide, IBERDOMIDE, IBERDOMIDA, IBERDOMIDE (CC220)

Parent form; salt/anhydrous children: CHEMBL3989912

Patent coverage: 468 distinct patent families (1,300 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,011 (78%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CRBN	cereblon	Binding	7.22	0.2%	Q96SW2

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Tumor necrosis factor, Interleukin-1 beta, Protein cereblon, Cereblon/Ikaros, Protein cereblon/Zinc finger protein Aiolos, Protein cereblon/DNA damage-binding protein 1, Zinc finger protein Aiolos.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
IL1B	9.34	IC50	0.46	nM	CHEMBL_ACT_26678708
CRBN	9.3	EC50	0.5	nM	CHEMBL_ACT_18565667
TNF	9.23	IC50	0.59	nM	CHEMBL_ACT_26678723
IKZF1	9	EC50	1	nM	CHEMBL_ACT_18565670
IKZF3	9	EC50	1	nM	CHEMBL_ACT_25673124
CRBN	7.89	IC50	12.8	nM	CHEMBL_ACT_25684977
DDB1	7.77	IC50	17	nM	CHEMBL_ACT_25673076
CRBN	7.22	IC50	60	nM	CHEMBL_ACT_18565675
CRBN	5.31	Ki	4940	nM	CHEMBL_ACT_22446531

Target pathways

Aggregated over 1 target gene(s): CRBN.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
Potential therapeutics for SARS	1	CRBN

Dominant GO biological processes

GO term	Targets
protein ubiquitination	1
positive regulation of Wnt signaling pathway	1
negative regulation of protein-containing complex assembly	1
positive regulation of protein-containing complex assembly	1
negative regulation of monoatomic ion transmembrane transport	1
locomotory exploration behavior	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
limb development	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
kidney failure	1	MONDO:0001106	HP:0000083

Clinical trials

Total trials: 47.

Phase distribution

Phase	Trials
PHASE1	17
PHASE2	12
PHASE1/PHASE2	12
PHASE3	4
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04975997	PHASE3	ACTIVE_NOT_RECRUITING	Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05558319	PHASE3	NOT_YET_RECRUITING	NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
NCT05827016	PHASE3	RECRUITING	A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT06216158	PHASE3	RECRUITING	Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
NCT02773030	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT04564703	PHASE2	ACTIVE_NOT_RECRUITING	Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
NCT04998786	PHASE2	ACTIVE_NOT_RECRUITING	A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.
NCT05177536	PHASE2	ACTIVE_NOT_RECRUITING	Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
NCT05199311	PHASE1/PHASE2	RECRUITING	Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
NCT05272826	PHASE2	RECRUITING	Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
NCT05354557	PHASE2	ACTIVE_NOT_RECRUITING	Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
NCT05392946	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
NCT05434689	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
NCT05527340	PHASE2	ACTIVE_NOT_RECRUITING	Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
NCT05583617	PHASE1/PHASE2	RECRUITING	A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
NCT05896228	PHASE2	RECRUITING	Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
NCT06107738	PHASE2	RECRUITING	Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
NCT06179888	PHASE2	RECRUITING	Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT06232044	PHASE1/PHASE2	RECRUITING	Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
NCT06518551	PHASE1/PHASE2	RECRUITING	Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT06762769	PHASE2	RECRUITING	Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
NCT06785415	PHASE1/PHASE2	RECRUITING	Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
NCT07437963	PHASE1/PHASE2	NOT_YET_RECRUITING	Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
NCT02185040	PHASE2	COMPLETED	A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
NCT03161483	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
NCT03310619	PHASE1/PHASE2	COMPLETED	A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
NCT04855136	PHASE1/PHASE2	TERMINATED	Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
NCT04882163	PHASE1/PHASE2	WITHDRAWN	Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
NCT04884035	PHASE1	RECRUITING	Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
NCT05169515	PHASE1	RECRUITING	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT06121843	PHASE1	RECRUITING	A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06215118	PHASE1	RECRUITING	A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06348108	PHASE1	RECRUITING	Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
NCT06465316	PHASE1	RECRUITING	Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
NCT06896916	PHASE1	RECRUITING	Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT01733875	PHASE1	COMPLETED	2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects
NCT02034773	PHASE1	COMPLETED	3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
NCT02820935	PHASE1	COMPLETED	Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects
NCT03135509	PHASE1	COMPLETED	A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects
NCT03294603	PHASE1	COMPLETED	Radiolabeled Study of CC-220 in Healthy Male Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

18 molecules share ≥1 primary target. Top 18 by shared-target count:

Molecule	Source	Status	Shared targets
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	CRBN
POMALIDOMIDE	ChEMBL + PubChem	Phase 4 (approved)	CRBN
ASCIMINIB	ChEMBL	Phase 4 (approved)	CRBN
BRIGATINIB	ChEMBL	Phase 4 (approved)	CRBN
DASABUVIR	ChEMBL	Phase 4 (approved)	CRBN
LENALIDOMIDE	ChEMBL	Phase 4 (approved)	CRBN
PONATINIB	ChEMBL	Phase 4 (approved)	CRBN
THALIDOMIDE	ChEMBL	Phase 4 (approved)	CRBN
MEZIGDOMIDE	ChEMBL	Phase 3	CRBN
URACIL	ChEMBL	Phase 3	CRBN
VEPDEGESTRANT	ChEMBL	Phase 3	CRBN
ADAVOSERTIB	ChEMBL	Phase 2	CRBN
AVADOMIDE	ChEMBL	Phase 2	CRBN
E-7820	ChEMBL	Phase 2	CRBN
FORETINIB	ChEMBL	Phase 2	CRBN
INDISULAM	ChEMBL	Phase 2	CRBN
Fulvestrant	PubChem	Approved	CRBN
Sotorasib	PubChem	Approved	CRBN